Media ReleasesCircadian

View All Circadian News


CEO on IND status for VGX-100

In this Open Briefing, CEO & MD Robert Klupacs discusses

- Clinical and commercial implications of IND status for VGX-100
- Design, end points and time lines of Phase I trials
- Outlook and value points for Circadian shareholders


For further information please download PDF below:

Download this document